In R/R DLBCL a phase II trial is ongoing assessing ruxolitinib in R/R DLBCL (NCT01431209), and synergizing effects are evaluated in the combination of JAK1 inhibitor, itacitinib, with ibrutinib (NCT02760485). This evidence concerns the gene JAK1 and diffuse large B-cell lymphoma.